JP2021157809A - 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム - Google Patents
非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム Download PDFInfo
- Publication number
- JP2021157809A JP2021157809A JP2021092697A JP2021092697A JP2021157809A JP 2021157809 A JP2021157809 A JP 2021157809A JP 2021092697 A JP2021092697 A JP 2021092697A JP 2021092697 A JP2021092697 A JP 2021092697A JP 2021157809 A JP2021157809 A JP 2021157809A
- Authority
- JP
- Japan
- Prior art keywords
- coding
- gene
- coding gene
- expression
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 190
- 230000004186 co-expression Effects 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000013507 mapping Methods 0.000 claims abstract description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 24
- 230000002596 correlated effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 102000042567 non-coding RNA Human genes 0.000 description 6
- 108091027963 non-coding RNA Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011524 similarity measure Methods 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100039145 Trefoil factor 3 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 101150060644 ARG3 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 101100462418 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ARG3 gene Proteins 0.000 description 1
- 101150048087 TFF3 gene Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Data Mining & Analysis (AREA)
- Physiology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Description
であり、ここで、σは標準偏差であり、Covは共分散である。コード遺伝子及び非コード遺伝子対のすべてについて計算された相関値が、共発現ネットワークを生成するのに使用されることができる。
Claims (20)
- 共発現されるコード遺伝子及び非コード遺伝子を特定する方法において、
複数のRNA配列をデジタル形式でメモリにおいて受信するステップと、
データベースにおけるコード遺伝子のセットに基づき、前記複数のRNA配列の少なくとも1つをコード遺伝子にマッピングするステップと、
前記複数のRNA配列の別の少なくとも1つを非コード遺伝子にマッピングするステップと、
少なくとも1つのプロセッサを用いて、前記コード遺伝子及び前記非コード遺伝子を相関させるステップと、
前記相関の結果に少なくとも部分的に基づき共発現ネットワークを生成するステップとを有する、方法。 - 前記コード遺伝子と前記非コード遺伝子とを相関させるステップが、ピアソン相関を適用するステップを有する、請求項1に記載の方法。
- 前記共発現ネットワークに少なくとも部分的に基づき、モジュールを生成するステップを更に有する、請求項1に記載の方法。
- 前記モジュールを生成するステップが、マルコフクラスタアルゴリズムを適用するステップを有する、請求項1に記載の方法。
- 前記共発現ネットワークに少なくとも部分的に基づき、コード遺伝子及び非コード遺伝子パートナーを特定するステップを更に有する、請求項1に記載の方法。
- 前記コード遺伝子及び非コード遺伝子パートナーが、遺伝子発現経路にある、請求項5に記載の方法。
- 前記コード遺伝子及び非コード遺伝子対が、シスである、請求項5に記載の方法。
- 前記コード遺伝子及び非コード遺伝子対が、トランスである、請求項5に記載の方法。
- 前記コード遺伝子の可変性及び前記非コード遺伝子の可変性を決定するステップを更に有する、請求項1に記載の方法。
- 複数のRNA配列をデジタル形式でメモリにおいて受信するステップと、
データベースにおけるコード遺伝子のセットに基づき、前記複数のRNA配列のいくつかをコード遺伝子にマッピングするステップと、
前記複数のRNA配列の別のいくつかを非コード遺伝子にマッピングするステップと、
前記コード遺伝子及び前記非コード遺伝子の可変性を決定するステップと、
閾値を超える可変性を持つ前記コード遺伝子及び非コード遺伝子を選択するステップと、
前記選択されたコード遺伝子及び前記非コード遺伝子を少なくとも1つのプロセッサを用いて相関させるステップと、
前記相関の結果に少なくとも部分的に基づき、共発現ネットワークを生成するステップとを有する、方法。 - 前記閾値が、75パーセンタイルである、請求項10に記載の方法。
- 前記選択されたコード遺伝子を互いに相関させるステップを更に有する、請求項10に記載の方法。
- 前記選択された非コード遺伝子を互いに相関させるステップを更に有する、請求項10に記載の方法。
- 前記複数のRNA配列の別のいくつかを非コード遺伝子にマッピングするステップが、前記データベースにおける非コード遺伝子のセットに基づかれる、請求項10に記載の方法。
- 非コード遺伝子に対する前記複数のRNA配列の別のいくつかが、長い非コーディングRNA配列を有する、請求項10に記載の方法。
- 前記複数のRNA配列が、疾患状態に由来する、請求項10に記載の方法。
- システムであって、
少なくとも1つのプロセッサと、
前記少なくとも1つのプロセッサにアクセス可能なメモリであって、デジタル形式で遺伝子配列を格納するよう構成されるメモリと、
前記少なくとも1つのプロセッサにアクセス可能なデータベースと、
前記少なくとも1つのプロセッサに結合されるディスプレイと、
命令でエンコードされた非一時的なコンピュータ可読媒体であって、前記命令が実行されるとき、前記少なくとも1つのプロセッサに、
前記メモリから前記遺伝子配列を受信させ、
データベースにおけるコード遺伝子のセットに基づき、前記遺伝子配列のいくつかをコード遺伝子にマッピングさせ、
前記遺伝子配列の別のいくつかを非コード遺伝子にマッピングさせ、
前記コード遺伝子及び前記非コード遺伝子の可変性を計算させ、
閾値を上回る可変性を持つ前記コード遺伝子及び非コード遺伝子を選択させ、
前記選択されたコード遺伝子及び非コード遺伝子の共発現を決定するため、前記選択されたコード遺伝子及び非コード遺伝子を相関させ、
前記共発現に少なくとも部分的に基づき、共発現ネットワークを生成させ、
前記ディスプレイにおいてユーザに対して前記共発現ネットワークを提供させる、非一時的なコンピュータ可読媒体とを有する、システム。 - 前記命令が実行されるとき、前記少なくとも1つのプロセッサに更に、前記共発現ネットワークに少なくとも部分的に基づき、ドラッガブル標的を選択させる、請求項17に記載のシステム。
- 前記命令が実行されるとき、前記少なくとも1つのプロセッサに更に、前記共発現ネットワークに少なくとも部分的に基づき、患者を階層化させる、請求項17に記載のシステム。
- 前記命令が実行されるとき、前記少なくとも1つのプロセッサに更に、前記共発現ネットワークに少なくとも部分的に基づき、疾患治療を選択させる、請求項17に記載のシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462090127P | 2014-12-10 | 2014-12-10 | |
US62/090,127 | 2014-12-10 | ||
JP2017528993A JP6932080B2 (ja) | 2014-12-10 | 2015-12-07 | 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017528993A Division JP6932080B2 (ja) | 2014-12-10 | 2015-12-07 | 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021157809A true JP2021157809A (ja) | 2021-10-07 |
JP7357023B2 JP7357023B2 (ja) | 2023-10-05 |
Family
ID=55024188
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017528993A Active JP6932080B2 (ja) | 2014-12-10 | 2015-12-07 | 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム |
JP2021092697A Active JP7357023B2 (ja) | 2014-12-10 | 2021-06-02 | 非コード-コード遺伝子共発現ネットワークを生成する方法及びシステム |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017528993A Active JP6932080B2 (ja) | 2014-12-10 | 2015-12-07 | 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム |
Country Status (7)
Country | Link |
---|---|
US (1) | US20170364633A1 (ja) |
EP (1) | EP3230911A1 (ja) |
JP (2) | JP6932080B2 (ja) |
CN (1) | CN107111689B (ja) |
BR (1) | BR112017012087A2 (ja) |
RU (1) | RU2017124373A (ja) |
WO (1) | WO2016092444A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017012087A2 (pt) * | 2014-12-10 | 2018-01-16 | Koninklijke Philips Nv | métodos de identificação de genes codificantes e não codificantes coexpressados, e sistema |
CN111276182B (zh) * | 2020-01-21 | 2023-06-20 | 中南民族大学 | Rna序列编码潜力的计算方法及系统 |
CN111899788B (zh) * | 2020-07-06 | 2023-08-18 | 李霞 | 一种非编码rna调控疾病风险靶通路的识别方法及系统 |
CN113539360B (zh) * | 2021-07-21 | 2023-03-31 | 西北工业大学 | 一种基于相关性优化和免疫富集的lncRNA特征识别方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080118576A1 (en) * | 2006-08-28 | 2008-05-22 | Dan Theodorescu | Prediction of an agent's or agents' activity across different cells and tissue types |
JP2008293505A (ja) * | 2003-03-28 | 2008-12-04 | Anesiva Inc | 調節因子結合部位のゲノムプロファイリング |
JP2010535473A (ja) * | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ncRNAをコードする超保存領域 |
JP2011509660A (ja) * | 2008-01-14 | 2011-03-31 | アプライド バイオシステムズ, エルエルシー | リボ核酸を検出するための組成物、方法およびキット |
JP2014517687A (ja) * | 2011-05-02 | 2014-07-24 | ボード・オブ・リージェンツ・オブ・ザ・ユニヴァーシティ・オブ・ネブラスカ | 有用な特徴を有する植物および関連する方法 |
JP2014532428A (ja) * | 2011-11-08 | 2014-12-08 | ジェノミック ヘルス, インコーポレイテッド | 乳癌の予後を予測する方法 |
JP6932080B2 (ja) * | 2014-12-10 | 2021-09-08 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7162465B2 (en) * | 2001-12-21 | 2007-01-09 | Tor-Kristian Jenssen | System for analyzing occurrences of logical concepts in text documents |
US8245150B2 (en) * | 2004-11-22 | 2012-08-14 | Caterpillar Inc. | Parts catalog system |
EP2672394A1 (en) * | 2012-06-04 | 2013-12-11 | Thomas Bryce | Methods and systems for generating reports in diagnostic imaging |
CN102994536A (zh) * | 2013-01-08 | 2013-03-27 | 内蒙古大学 | 双顺反子共表达基因转移体及制备方法 |
CN104388373A (zh) * | 2014-12-10 | 2015-03-04 | 江南大学 | 一种共表达羰基还原酶和葡萄糖脱氢酶的大肠杆菌系统的构建 |
-
2015
- 2015-12-07 BR BR112017012087A patent/BR112017012087A2/pt not_active Application Discontinuation
- 2015-12-07 EP EP15816532.4A patent/EP3230911A1/en not_active Withdrawn
- 2015-12-07 JP JP2017528993A patent/JP6932080B2/ja active Active
- 2015-12-07 US US15/533,407 patent/US20170364633A1/en not_active Abandoned
- 2015-12-07 CN CN201580072759.3A patent/CN107111689B/zh active Active
- 2015-12-07 RU RU2017124373A patent/RU2017124373A/ru not_active Application Discontinuation
- 2015-12-07 WO PCT/IB2015/059389 patent/WO2016092444A1/en active Application Filing
-
2021
- 2021-06-02 JP JP2021092697A patent/JP7357023B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008293505A (ja) * | 2003-03-28 | 2008-12-04 | Anesiva Inc | 調節因子結合部位のゲノムプロファイリング |
US20080118576A1 (en) * | 2006-08-28 | 2008-05-22 | Dan Theodorescu | Prediction of an agent's or agents' activity across different cells and tissue types |
JP2010535473A (ja) * | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ncRNAをコードする超保存領域 |
JP2011509660A (ja) * | 2008-01-14 | 2011-03-31 | アプライド バイオシステムズ, エルエルシー | リボ核酸を検出するための組成物、方法およびキット |
JP2014517687A (ja) * | 2011-05-02 | 2014-07-24 | ボード・オブ・リージェンツ・オブ・ザ・ユニヴァーシティ・オブ・ネブラスカ | 有用な特徴を有する植物および関連する方法 |
JP2014532428A (ja) * | 2011-11-08 | 2014-12-08 | ジェノミック ヘルス, インコーポレイテッド | 乳癌の予後を予測する方法 |
JP6932080B2 (ja) * | 2014-12-10 | 2021-09-08 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 非コード−コード遺伝子共発現ネットワークを生成する方法及びシステム |
Non-Patent Citations (1)
Title |
---|
NILANJANA BANERJEE: "Identifying RNAseq-based coding-noncoding co-expression interactions in breast cancer", 2013 IEEE INTERNATIONAL WORKSHOP ON GENOMIC SIGNAL PROCESSING AND STATISTICS GENSIPS 2013, JPN6020004518, 17 November 2013 (2013-11-17), US, pages 11 - 14, XP032564432, ISSN: 0005064230, DOI: 10.1109/GENSIPS.2013.6735917 * |
Also Published As
Publication number | Publication date |
---|---|
JP6932080B2 (ja) | 2021-09-08 |
EP3230911A1 (en) | 2017-10-18 |
CN107111689A (zh) | 2017-08-29 |
RU2017124373A (ru) | 2019-01-10 |
JP7357023B2 (ja) | 2023-10-05 |
CN107111689B (zh) | 2021-12-07 |
WO2016092444A1 (en) | 2016-06-16 |
JP2018504669A (ja) | 2018-02-15 |
US20170364633A1 (en) | 2017-12-21 |
BR112017012087A2 (pt) | 2018-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van Dam et al. | Gene co-expression analysis for functional classification and gene–disease predictions | |
JP7357023B2 (ja) | 非コード-コード遺伝子共発現ネットワークを生成する方法及びシステム | |
Rahman et al. | Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results | |
Bandyopadhyay et al. | MBSTAR: multiple instance learning for predicting specific functional binding sites in microRNA targets | |
Withnell et al. | XOmiVAE: an interpretable deep learning model for cancer classification using high-dimensional omics data | |
JP7041614B2 (ja) | 生体データにおけるパターン認識のマルチレベルアーキテクチャ | |
AU2013329319A1 (en) | Systems and methods for learning and identification of regulatory interactions in biological pathways | |
WO2020028989A1 (en) | Systems and methods for determining effects of therapies and genetic variation on polyadenylation site selection | |
Zhao et al. | RWLPAP: random walk for lncRNA-protein associations prediction | |
Li et al. | PROBer provides a general toolkit for analyzing sequencing-based toeprinting assays | |
WO2019242445A1 (zh) | 病原体操作组的检测方法、装置、计算机设备和存储介质 | |
Liang et al. | Rm-LR: A long-range-based deep learning model for predicting multiple types of RNA modifications | |
WO2018165762A1 (en) | Systems and methods for determining effects of genetic variation on splice site selection | |
Yang et al. | MSPL: Multimodal self-paced learning for multi-omics feature selection and data integration | |
KR100668413B1 (ko) | 유전자의 발현 패턴 데이터와 단백질 상호작용 데이터를이용한 유전자 패스웨이 예측 방법 및 시스템 | |
US20160055294A1 (en) | Method and apparatus for determining transcription factor for biological process | |
Borisov et al. | Uniformly shaped harmonization combines human transcriptomic data from different platforms while retaining their biological properties and differential gene expression patterns | |
Abondio et al. | Single Cell Multiomic Approaches to Disentangle T Cell Heterogeneity | |
Uthayopas et al. | PRIMITI: a computational approach for accurate prediction of miRNA-target mRNA interaction | |
Li et al. | Prober: A general toolkit for analyzing sequencing-based ‘toeprinting’assays | |
Olorunshola | Classifying Different Cancer Types Based on Transcriptomics Data Using Machine Learning Algorithms | |
Liu et al. | A novel clustering method for patient stratification | |
US20200058375A1 (en) | Variant-specific alignment of nucleic acid sequencing data | |
Yeung | Signature discovery for personalized medicine | |
JP2023029827A (ja) | バリアントコールのためのニューラルネットワーク |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210630 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230814 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230925 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7357023 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |